Securities code: 688488 securities abbreviation: Jiangsu Aidea Pharmaceutical Co.Ltd(688488) Announcement No.: 2022-002 Jiangsu Aidea Pharmaceutical Co.Ltd(688488)
Announcement of resolutions of the first extraordinary general meeting of shareholders in 2022
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of the announcement, and bear legal liabilities for the authenticity, accuracy and completeness of the contents according to law. Important content: whether there is any proposal rejected at this meeting: none. Convening and attendance of the meeting
(I) time of the general meeting of shareholders: January 11, 2022
(II) place of the general meeting of shareholders: conference room (III) on the first floor, No. 69, xinganquan West Road, Hanjiang District, Yangzhou city. Information on ordinary shareholders, shareholders with special voting rights, preferred shareholders whose voting rights have been restored and the number of voting rights held:
1. Number of shareholders and proxies attending the meeting 14
Number of ordinary shareholders 14
2. The number of voting rights held by shareholders attending the meeting is 256774712
Number of voting rights held by ordinary shareholders 256774712
3. Proportion of the number of voting rights held by shareholders attending the meeting to the number of voting rights of the company
Cases (%) 61.1368
Proportion of the number of voting rights held by ordinary shareholders in the number of voting rights of the company (%) 61.1368
(IV) whether the voting method complies with the provisions of the company law and the articles of association, the chairmanship of the general meeting, etc.
The general meeting of shareholders was convened by the board of directors of the company and presided over by Mr. Fu Heliang, chairman of the board of directors. It was held by combining on-site voting and online voting. The convening, convening and voting methods of this meeting comply with the relevant provisions of the company law, the Listing Rules of the science and Innovation Board of Shanghai Stock Exchange and the articles of association. (V) attendance of directors, supervisors and Secretary of the board of directors of the company 1. There were 9 incumbent directors of the company and 9 attended the meeting, including Mr. Fu Heliang, Mr. Yu Ke and Mr. Wang Jun, and other directors attended the meeting by video; 2. There are 3 supervisors in office and 3 present; 3. Ms. Wang Guangrong, Secretary of the board of directors, attended the meeting by video; Other executives of the company attended the meeting as nonvoting delegates. 2、 Deliberation of the proposal (I) non cumulative voting proposal 1. Title of the proposal: proposal on changing some investment projects with raised funds and adding their implementation subjects. Deliberation results: passed
Voting:
Agree against waiver
Type of shareholders proportion of votes proportion of votes (%) (%) (%)
Common stock 256770803 99.9984 3909 0.0016 0.0000
2. Proposal Name: proposal on signing technology transfer contract with Guangzhou Lixin Biotechnology Co., Ltd
Outcome: adopted
Voting:
Agree against waiver
Type of shareholders proportion of votes proportion of votes (%) (%) (%)
Common stock 256774712 100.0000 0.0000 0.0000
3. Proposal Name: proposal on continuing the appointment of accounting firms
Outcome: adopted
Voting:
Types of shareholders agree against waiver
Proportion of votes proportion of votes (%) (%)
Common stock 256767010 99.9970 7702 0.0030 0 0.0000
(II) if major matters are involved, the voting situation of less than 5% shareholders shall be explained
The motion agreed to oppose abstention
No. proposal name number of votes proportion of votes proportion of votes (%) (%) number of votes (%)
About change department
Sub raised fund investment
1. Investment projects and newly added 48410465 99.9919 3909 0.0081 0.0000
Proposal
About and Guangzhou
Lixin Biotechnology
2. The company signed 48414374 100.0000 0.0000 0.0000 ＜ technology transfer contract
Proposal of the same
About renewal meeting
3. 48406672 99.9840 7702 0.0160 0.0000 proposal of the accounting firm
(III) explanation on the voting of proposals 1. All the proposals considered at the shareholders’ meeting were considered and passed; 2. Proposals 1, 2 and 3 of the general meeting of shareholders separately counted votes for small and medium-sized investors. 3、 Witness by lawyers 1. Law firm witnessed at the shareholders’ meeting: Shanghai Chengming Zezheng law firm
Lawyer: Zhang Qingyang, Liu Lu 2. Lawyer’s Witness conclusion:
Our lawyers believe that: Jiangsu Aidea Pharmaceutical Co.Ltd(688488) the convening and convening procedures of the first extraordinary general meeting of shareholders in 2022 comply with the provisions of laws, administrative regulations, rules of procedure of the general meeting of shareholders and the articles of Association; The qualifications of the personnel attending the shareholders’ meeting and the convener are legal and valid; The voting procedures and results of this general meeting of shareholders are legal and valid.
It is hereby announced.
Jiangsu Aidea Pharmaceutical Co.Ltd(688488) daily report of the board of directors on January 12, 2022 for filing
(I) Jiangsu Aidea Pharmaceutical Co.Ltd(688488) the resolution of the first extraordinary general meeting of shareholders in 2022;
(II) legal opinion of Shanghai Chengming Zezheng law firm on Jiangsu Aidea Pharmaceutical Co.Ltd(688488) the first extraordinary general meeting of shareholders in 2022.
